نتایج جستجو برای: immunosuppressive factor

تعداد نتایج: 863068  

2001
ELLEN C. EBERT Ellen C. Ebert

The colon cancer cell line, HT29, produces a soluble substance (HT29 factor) that blocks mitogeninduced T cell proliferation and the production of interleukin 2 (IL 2). Inhibition of T cell proliferation by the HT29 factor is reversible and is not due to a decline in cell viability or an alteration in the kinetics of T cell proliferation. I t occurs even when the HT29 factor is added only 24 hr...

Journal: :مجله بین المللی کودکان و نوجوانان 0
reza saidi division of organ transplantation, department of surgery

kidney transplantation in children is the treatment of choice to treat end stage renal disease. improvements in immunosuppressive management have dramatically reduced the risk of early acute rejection and graft loss, however the long term results in terms of graft survival and morbidity still require search for new immunosuppressive regimens. reducing of side effects are the challenges for impr...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 1995
K T Shaw A M Ho A Raghavan J Kim J Jain J Park S Sharma A Rao P G Hogan

The immunosuppressive drugs cyclosporin A and FK506 interfere with the inducible transcription of cytokine genes in T cells and in other immune cells, in part by preventing the activation of NF-AT (nuclear factor of activated T cells). We show that transcription factor NFAT1 in T cells is rapidly dephosphorylated on stimulation, that dephosphorylation occurs before translocation of NFAT1 into t...

2015
Eva Zavadova Michal Vocka Jan Spacek Nicole Francis Bohuslav Konopasek Terezie Fucikova Helena Skalova Pavel Dundr Lubos Petruzelka Tilman T Rau Carol Geppert Arndt Hartmann

Immunoscore has been shown to be a very powerful prognositc indicator in patients with clinically localized colorectal cancer, with no detectable tumour spread to lymph nodes or distant organs. These patients are usually treated with surgical removal of the tumour only. However, approximately 25% of these patients will have recurrence of their disease. No tumour-associated marker to predict the...

Journal: :The Netherlands journal of medicine 2013
C V Bakker S H Kardaun K R Wilting G F H Diercks B Horváth

Patients who use immunosuppressive agents, in particular medication that blocks tumour necrosis factor-a, are at risk for mycobacterial infections. Besides the typical Mycobacterium tuberculosis infection, a lso a typical mycobacterial disease may occur. Here we demonstrate two patients with such atypical mycobacterial infection due to swimming and fishing water contact. We propose that patient...

Journal: :Oncology reports 2006
Yoshiki Yamamoto Yuji Ueda Tsuyoshi Itoh Arihiro Iwamoto Hisakazu Yamagishi Masaaki Shimagaki Kazuo Teramoto

Immune responses are frequently depressed in patients with cancer. One of the reasons for a poor immune response is the presence of increased levels of immunosuppressive substances associated with tumor growth. Transforming growth factor-beta (TGF-beta), a representative immunosuppressive cytokine, plays various roles in the progression of cancer. To remove immunosuppressive substances from tum...

Journal: :Blood advances 2017
Raghavan Chinnadurai Devi Rajan Spencer Ng Kenneth McCullough Dalia Arafat Edmund K Waller Larry J Anderson Greg Gibson Jacques Galipeau

Industrial-scale expansion of mesenchymal stromal cells (MSCs) is often used in clinical trials, and the effect of replicative senescence on MSC functionality is of mechanistic interest. Senescent MSCs exhibit cell-cycle arrest, cellular hypertrophy, and express the senescent marker β-galactosidase. Although both fit and senescent MSCs display intact lung-homing properties in vivo, senescent MS...

Journal: :iranian journal of pharmaceutical sciences 0
hashem montaseria department of pharmaceutics hasan merrikhi department of toxicology and pharmacology, faculty of pharmacy, shiraz university of medical sciences, shiraz, iran mohammad javad khoshnoud assistance professor, department of toxicology and pharmacology, faculty of pharmacy, shiraz university of medical sciences, shiraz, iran bita geramizadeh department of pathology, faculty of medicine, shiraz university of medical sciences, shiraz, iran

sirolimus is a potent immunosuppressive agent administered as prophylactic agent to prevent rejection after organ transplantation. sirolimus must be used within a narrow therapeutic window. due to inter- and intra-variability, sirolimus blood concentrations may be affected, therefore, there is no possibility of predicting the sirolimus blood concentrations based on the dose patients received. t...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید